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Objectives. In December 2012, a new technique for treating low-risk prostate cancer was launched at the “Hospital Universitario
Marqués de Valdecilla” (HUMV): the prostate low-dose rate (LDR) brachytherapy. Up to this date, patients from Cantabria choos-
ing this technique were derived to other Autonomous Communities. The objective of this study is to analyze the costs of the
implementation of this technique and compare them to the previous situation.
Methods. We have estimated the costs of the method in collaboration with the “Subdirección de Gestión Económica y Pre-
supuestos” of the HUMV. For the derivation costs we have taken into account travel and maintenance costs as well as the
value of the amount of the prostatic brachytherapy as reﬂected in Annex II from the Order SSI/2687/2012.
Result. The cost of the prostate LDR brachytherapy in the HUMV is 5537D per patient. This value is lower than that included in the
Order SAN 12/2011 for other therapeutic options. The average number of patients derived to other autonomous communities is
50 per year. This has a cost of 10,883D per patient for the Government of Cantabria.
Conclusion. The annual net proﬁt of the implementation of the prostate LDR brachytherapy is 267.300D. The start-up of this
technique has been assumed by the HUMV without any personnel increase and will prevent 50 patients per year from moving
out of Cantabria to undergo this treatment.
http://dx.doi.org/10.1016/j.rpor.2013.03.036
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Purpose. Evaluation of interstitial high-dose-rate brachytherapy (HDRBT) both alone and in combination with external beam
radiotherapy (EBRT) recurrent gynecological malignancies in terms of toxicity.
Materials and methods. From 2007 to 2012, 25 women with a mean age of 56 years were treated with transperineal interstitial
HDRBT for recurrent gynecological malignancies. Primary sites included endometrium (4), vulva (2), vagina (5), cervix (14). All
patients were treated with radical intent. Three patients had received radiotherapy before (Median EQD2 [Equivalent Dose to 2Gy
per fraction] = 58.25Gy). Twenty-two patients received EBRT with EQD2 doses between 44 and 50Gy (median, 45Gy) of EBRT. The
HDRBT doses ranged from 3.3 to 11Gy per fraction. Fourteen patients received 1 implant and 11 patients received 2 implants.
One to six fractions per implant were delivered. The total EQD2 for HDRBT was 28Gy (range 14–70). The total (EBRT+HDRBT)
EQD2 was 72Gy (range 35–80).
Results. Median reference volume (Vref) was 100 cm3 (range 42–189). Median volume receiving 150% of the reference dose (V150)
was 30cc (range 10–69). Median volume receiving 200% of the reference volume (V200) was 11cc (range 4–29). EQD2 doses
(EBRT+HDRBT) to the hottest 1cc (D1) and 2cc (D2) in the organs at risk were as follow: median rectum D1=56Gy (3.8–83),
D2=56Gy (3–79). Median bladder D1=56Gy (3.8–90), D2=55Gy (3–90). Acute grade≥3 toxicity was seen in 1 (4%) of the 25 patients
(urinary G4). Late grade≥3 toxicitywas seen in 2 (7.6%) patients (urinary G3, skin G4). No correlationwas seen between dosimetric
parameters and the onset of acute or cronic toxicity.
Conclusion. The use of interstitial HDRBT seems safe for the treatment of recurrent gynecological malignancies. Late toxicity is
not correlated with dosimetric parameters in this series.
http://dx.doi.org/10.1016/j.rpor.2013.03.037
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A 58 year old woman, diagnosed in June 2001 of an endometrial adenocarcinoma G1 stage IIA (cervical superﬁcial) treated
with surgery+external RT+endobronchial brachytherapy. In January 2007 she presents hemoptysis and occasional cough.
Complementary studies were made: Chest CT: the abdominal study only highlights the presence of multiple mesenteric lym-
phadenopathies. MRI: upper left lobe, mass of approx. 5.5 cm, includes the upper lobe bronchus with a mass within its light.
Extension studies were negative for metastases. Bronchoscopy: upper left lobe bronchus an endobronchial mass was observed.
The pathologist reported of a probably metastatic adenocarcinoma compatible and consistent with endometrial origin. In July
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2007 she was operated of a left upper lobectomy and lymphadenectomy. The pathology report consistent with metastatic ade-
nocarcinoma of endometrial origin of 4 cm in maximum diameter that do not invades the visceral pleura. The tumor near the
surgical resection margin invades and occludes the bronchial lumen completely. The prevascular lymphadenopathy was free
of tumor involvement. With the diagnosis of lung metastasis of an endometrial adenocarcinoma the patient was sent to our
service for local consolidation therapy. Treatment plan, we administered 30Gy in 6 fractions to the bronchial stump, 5Gy each
session, from 27 September to October 31 of 2007. In each session were performed a bronchoscopy and a dosimetric planning
CT. Tolerance to treatment was excellent. Last control CT was in 3/2012 and informed of a complete response.
Conclusion. After ﬁve year the patient remains disease free. Endobronchial brachytherapy is an effective alternative to achieve
local control after surgery of metastasis.
http://dx.doi.org/10.1016/j.rpor.2013.03.038
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Objective. Review the results of toxicity in patients (p) with prostate cancer treated with permanent brachytherapy with seeds of
I125.
Material and methods. Criteria of incorporation: p with low risk prostate cancer dose 145Gy; intermediate risk, combined Exter-
nal Radiotherapy 45Gy and 110Gy; all had prostate volume <45 cm3 and IPSS minor than 12. The planning system was real
time intraoperatory system SPOT, and SEED-Selectron (Nucletron®). We followed ESTRO guidelines and dose was registered in
neurovascular bundles by D90. IPSS and toxicity has been recorded according to the scale CTC v.4 at diagnosis and the reviews.
Results. 121 patients included (p) in the period of Dic 2008 to Dec 2012. The treatment was exclusive in 95 p (77%) of low risk,
combined in 26p (23%) of intermediate risk. Characteristics: T1c: 99p (82%), T2a 17p (11%), T2c 5p (7%); Gleason 4–5: 2p (2%), 6:
95p (79%), 7: 24p (19%). Medium dose: D90 PTV: 162.2Gy (142.4–188.2); boost: 120.34 (110.3–129.5); D30 urethra md: 112%; D10
urethra med: 119%; D2cc rectum: 89.5%. With median of follow-up: 14.8m, biochemical and local failure (conﬁrmed PET-colina):
1p (0.8%). The toxicity to 12m includes: in the Table 1. G1 G2 G3 Frequency 1 (1.8%) 16 (13.2%) – Nicturia 25 (20.7%) 2 (1.7%) 1 (0.8%)
Incontinency 0 Proctitis 0 1 (0.8%) Impotence 6 (5%) 12 (9.9%). It has not been correlation between the toxicity urinary GII and
D10 uretral, neither impotence GII and D90 in neurovascular bundles: D90 No impotence: 93.8Gy vs D90 G1–2: 98.1Gy (p: ns).
Conclusion. Intraoperatory real time planning reduces late urinary and sexual toxicity. We did not ﬁnd correlation between the
urinary toxicity GII and D10 uretral, neither impotence GII and D90 in neurovascular bundle, although a major follow-up is
necessary.
http://dx.doi.org/10.1016/j.rpor.2013.03.039
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Introduction. Brachytherapy with 125-I seeds in low-intermediate risk prostate carcinoma is a very save treatment, if we respect
the constraint over rectum and urethra as ESTRO recommend Objective Analysis dose to rectum and urethra at our institution
on incorporation of brachytherapy with permanent implants of 125-I seeds in prostate carcinoma with real-time planiﬁcation
and Quick-Link system.
Methods. Between March of 2011 and December of 2012 were performed 41 prostate brachytherapy applications with permanent
implants of 125-I seeds in patients with prostate Adenocarcinoma low-intermediate risk, as monotherapy or combined with
EBRT. Of this patients 87.8% were ≤T2a, 12.2% T2b-c. Mean PSA: 6.73ng/ml (range 4.06–16.7). 87.8% were Gleason≤6 and 7 (3 + 4)
12.2%. Median Prostate volumen was 33 cm3, only one patient had volume 53.8 cm3. System Quick-Link was used with real-time
planiﬁcation, inserting a median of 16 needles and 60 seeds (range 38–82) to cover PTV with 145Gy isodose in radical intent
(92.6%) and 108Gy in combined with EBRT (7.4%) We used Constraints recommended by ESTRO: Uretra D10≤150Gy and during
the progress of learning curve was amended to Uretra D1≤150Gy. Rectum V100≤5%.
Results. Mean V100 in Rectum was 2.9% (between 0.1 and 9.68), 85% of patients with V100≤5% (35/41 patients). Mean D1 in
Uretra was 138Gy (between 121 and 196.8). 88% of patients with D1≤150Gy (36/41 patients). All patients had UrethraD10≤150Gy
following ESTRO recommendations. No patient had complications during the procedure and they all were discharged in the ﬁrst
24h. 1 patient (2.4%) required catheterization for acute urinary retention and there were no cases of acute rectal toxicity.
